louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04533009: Tramadol-paracetamol Combination in Treatment of Patients Undergoing Spinal Surgery
Official title: Tramadol-paracetamol Combination in Treatment of Patients Undergoing Spinal Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pain, Postoperative
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
Collaborators: name: University of Eastern Finland
First posted: 2020-08-31
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomised, double blinded, placebo controlled study
Primary purpose: TREATMENT

Brief summary: Tramadol-paracetamol combination is studied in patients coming for elective spine surgery. The study drug is started at the day of surgery and continued maximum of five days. Before the surgery pain, use of pain medication, satisfaction for pain medication, adverse effects, resilience, depression and life satisfaction were asked. At the discharge and seven days after the surgery use of pain medication and adverse effects were asked. The patients were followed up to 28 days and one year after surgery.


Eligibility criteria: Inclusion Criteria:

* age 18-75 years,
* BMI 18-35 kg/m2,
* informed consent obtained,
* elective spine surgery

Exclusion Criteria:

* Age\<18 years or \>75 years
* Hypersensitivity to anti-inflammatory drugs, paracetamol, tramadol or their auxiliary substances
* Acute or recovered hemorrhage in gastrointestinal tract or peptic ulcer
* Hemorrhagic disease
* Monoamineoxidase use in past two weeks
* Epilepsy
* Tendency to seizure
* Anti-seizure drugs in use Liver or renal failure Reduction in lung function Alcohol, drug or opioid addiction on record Acute intoxication due to alcohol, analgesics, opioids or psychopharmacon Pregnancy or breastfeeding Investigators estimation

Primary outcomes:
measure: Satisfaction for pain medication
timeFrame: one week after surgery
Secondary outcomes:
measure: need for rescue pain medication
timeFrame: one week after surgery
measure: Pain assessment
timeFrame: one week after surgery
measure: adverse effects
timeFrame: one week after surgery
Other outcomes:
measure: Pain assessment
timeFrame: one year after surgery
Locations:
city: Kuopio
country: Finland
facility: Kuopio University Hospital
state: Northern Savo
Study officials:
affiliation: Kuopio University Hospital
name: Merja Kokki, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02099409: Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg
Official title: Open Label Single Center Randomized Cross Over Study to Validate Current Algorithms and Evaluate Safety and Efficacy of Closed Loop Insulin Delivery (FlorenceD2 System) in Children With Type 1 Diabetes Between 6 - 12 Years of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Keywords: Type 1 diabetes mellitus
children
closed loop
cross over
overnight
FLORENCED2
DANA Diabecare R pump
FreeStyle Navigator II
Dexcom G4
Lead sponsor: Centre Hospitalier du Luxembourg
Sponsor class: OTHER
Collaborators: name: University of Cambridge
First posted: 2014-03-28
Enrollment: 15
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to validate current algorithms and evaluate safety and efficacy of overnight closed loop insulin delivery (FlorenceD2 system) in children with type 1 diabetes between 6 - 12 years of age in Luxembourg .


Eligibility criteria: Inclusion Criteria:

* Between 6 - ≤12 years
* With type 1 diabetes for 6 months or more and
* Pump user for at least 6 months.
* HbAc1 should be \<11 %.
* No medication or physical or psychological disease should be present, which could interfere with the study.

Exclusion Criteria:

-None

Primary outcomes:
measure: Time spent in normal glucose range ( mg/dl)
timeFrame: At least 5 hours between 7 pm and 7 am
Secondary outcomes:
measure: glucose variability ( excursions in mg/dl)
timeFrame: 7 pm - 7 am
measure: Time spent in low glucose range (< 60 mg/dl)
timeFrame: 7 pm till 7 am
measure: time spent in low glucose range (<70 mg/dl)
timeFrame: 7 pm till 7 am
measure: time spent in high glucose range (>180mg/dl)
timeFrame: 7 pm - 7 am
Other outcomes:
Locations:
city: Luxembourg
country: Luxembourg
facility: DECCP Clinique Pédiatrique de Luxembourg/CHL
city: Luxembourg
country: Luxembourg
facility: DECCP Pediatric Clinic , CHLuxembourg
Study officials:
affiliation: Centre Hospitalier du Luxembourg
name: Carine deBeaufort, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Cambridge
name: Roman Hovorka, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Cambridge
name: Gosia Wilinska, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Hospitalier du Luxembourg
name: Ulrike Schierloh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02641509: Accuracy in Resection of Non-pedunculated Colonic Lesions 5-20 mm With/Without Using NBI
Official title: Accuracy in Resection of Non-pedunculated Colonic Lesions 5-20 mm With/Without Using NBI
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Polypectomy
Lead sponsor: Valduce Hospital
Sponsor class: OTHER
First posted: 2015-12-29
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Interval colon cancers are an important clinical issue. A recent paper from Pohl et al focused on non-pedunculated polyps of 5-20 mm, evaluating non complete polypectomy revealing that 10% of these polyps were not completely resected. This fact was attributed to size and histology. In this study the investigators want to evaluate the radical resection of non-pedunculated polyps of 5-20 mm by performing biopsies on the margins immediately after polypectomy, to establish if the use of Narrow Band Imaging (NBI) could be useful in the definition of the margins of the lesion before polypectomy.

Detailed description: Interval colon cancers are an important clinical issue. Literature dealing with technics and quality of polypectomy is scarce. A recent paper from Pohl et al focused on non-pedunculated polyps of 5-20 mm, evaluating non complete polypectomy and factors related to it, revealing that 10% of these polyps were not completely resected. This fact was attributed to size and histology (the majority of non completely resected ones, were polyps of 10-20 mm and with serrated characteristics at the histology). In this study the investigators want to evaluate the radical resection of non-pedunculated polyps of 5-20 mm by performing biopsies on the margins immediately after polypectomy, to establish if the use of Narrow Band Imaging (NBI) could be useful in the definition of the margins of the lesion before polypectomy.

Eligibility criteria: Inclusion Criteria:

* Every polyp ≥ 5 mm and ≤ 20 mm

Exclusion Criteria:

* Inflammatory bowel Disease and/or International Normalized Ratio \> 1.5

Primary outcomes:
measure: NBI efficacy in predicting radicality of polypectomy by taking random biopsies of margins after resection of the lesion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Como
country: Italy
facility: Valduce Hospital
Study officials:
References:
Clinical trial NCT05302609: Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface
Official title: Phase II Study: Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Scleral Thinning
Keywords: Ocular Oncology
Tumor Exeresis
Lead sponsor: TBF Genie Tissulaire
Sponsor class: INDUSTRY
First posted: 2022-03-31
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this open, multicenter phase II trial is to confirm the tolerance and evaluate the efficacy of the SclerFIX product, an allograft of umbilical cord lining membrane, in reinforcement of scleral thinning in patients who underwent eye tumor exeresis.

Detailed description: As scleral graft is forbidden in France, it cannot be used to reinforce the sclera. This study investigational product, SclerFIX, was developed to substitute scleral grafts.

Eligibility criteria: Inclusion Criteria:

* Male or female, aged 18 to 80 years.
* Patients with risk of perforation or deep loss of substance during surgical removal of a tumor of the ocular surface.
* Patient with loss of substance \< 3cm2.
* Patient able to understand, sign and date the informed consent form.
* Patient who is a member or a beneficiary of a national health insurance plan.

Exclusion Criteria:

* Pregnant or breastfeeding woman or woman of childbearing age without effective contraception.
* Patients with uncontrolled infectious risk.
* Patient with an autoimmune disease.
* Person deprived of liberty by a judicial or administrative decision.
* Person under forced psychiatric care.
* Person admitted to a health or social institution for purposes other than the research.
* Adult subjected to a legal protection measure or unable to express his / her consent.

Primary outcomes:
measure: Rate of tectonic success of the graft at 3 months
timeFrame: 3 months
Secondary outcomes:
measure: Absence of inflammatory reactions and good local tolerance of the implant
timeFrame: 15 days, 1 month, 3 months
measure: Evaluation of the visual acuity
timeFrame: 15 days, 1 month, 3 months
measure: Evaluation of the eye pressure
timeFrame: 15 days, 1 month, 3 months
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital de la Croix-Rousse, Hospices Civils de Lyon
city: Nice
country: France
facility: Hôpital Pasteur 2 - CHU de NICE
Study officials:
References:
Clinical trial NCT01531309: Pharmacokinetics of AGO178 in Participants With Liver Impairment
Official title: An Open-Label, Parallel-Group Study to Compare the Pharmacokinetics, Safety and Tolerability of a Single Sublingual 1 mg Dose of AGO178 in Subjects With Mild and Moderate Hepatic Impairment With That in Matched Healthy Control Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatic Impairment
Keywords: Liver impairment
Major Depression Disorder
Sublingual tablet
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Servier
First posted: 2012-02-10
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: AGO178 was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet). The goal of this trial was to study the pharmacokinetics of agomelatine given as sublingual tablet in participants with liver impairment and to compare the results to those of healthy volunteers who receive the same treatment.


Eligibility criteria: Inclusion Criteria:

* Participants with liver disease confirmed within 3 months of screening.
* If liver impairment is caused by alcohol use, participants must have abstained from alcohol use within 3 months of study start.
* Participants must satisfy criteria for Child- Pugh Class A or B.

Exclusion Criteria:

* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
* Pregnant or nursing (lactating) women.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless using effective contraception during the study.
* Donation or loss of 400 millilitres (mL) or more of blood within eight (8) weeks prior to initial dosing.
* Significant illness within the two weeks prior to the dosing.
* Participants with Child-Pugh alterations due to a non-liver disease (e.g. cancer or treatment related weight loss).

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax) of AGO178
timeFrame: Predose, 2 minute (min) , 5 min , 10 min, 20 min, 30 min, 45 min, 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 12h, 24h, 36h Post dose
measure: Area Under the Plasma Curve (AUC) of AGO178
timeFrame: Predose, 2 min , 5 min , 10 min, 20 min, 30 min, 45 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h, 36h Post dose
Secondary outcomes:
measure: Number of Participants with Adverse Events
timeFrame: Baseline and Day 8
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Clinical Research Center
state: Florida
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT03795909: Ruxolitinib Combined With Dexamethasone for HLH
Official title: Ruxolitinib Combined With Dexamethasone for Pediatric Refractory and Secondary Hemophagocytic Lymphohistiocytosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Hemophagocytic Lymphohistiocytosis
Lead sponsor: Capital Research Institute of Pediatrics
Sponsor class: OTHER_GOV
First posted: 2019-01-08
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.

Detailed description: A modified protocol about ruxolitinib combined with dexamethasone which includes oral ruxolitinib (2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）. Dexamethasone (10mg/m2.d) delayes for the first 2 weeks （form week 1 to 2），(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8. Every 2 weeks, patients can be evaluated based the diagnosed index

Eligibility criteria: Inclusion Criteria:

* Secondary and refractory HLH.

Exclusion Criteria:

* Family HLH.

Primary outcomes:
measure: Severity of disease
timeFrame: 2 weeks
Secondary outcomes:
measure: Axillary temperature
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Yan Yue
state: Chaoyang District
city: Beijing
country: China
facility: Yan Yue
Study officials:
affiliation: Capital Institute of Pediatrics, China
name: Yan Yue, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05849909: Evaluation of the Vulnerable Carotid Atherosclerotic Plaque: A Clinical Multicenter Study
Official title: Evaluation of the Vulnerable Carotid Atherosclerotic Plaque: A Clinical Multicenter Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ultrasound
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: Second Affiliated Hospital, School of Medicine, Zhejiang University
First posted: 2023-05-09
Enrollment: 57
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing carotid endarterectomy

Brief summary: Evaluation of carotid plaque vulnerability based on ultrasound imaging features， proteomics and metabolomics: a clinical multicenter study

Detailed description: Carotid artery plaque tissue specimen for proteomics. Blood were collect for metabolomics.

Eligibility criteria: Inclusion Criteria:

1. Patients who meet the CEA surgical indications;
2. Age\>18 years old;
3. Patients who sign informed consent forms

Exclusion Criteria:

1. Those with severe calcification of plaques and obvious acoustic shadows, and poor image quality;
2. Contraindications to ultrasound contrast, such as those who are allergic to contrast agents;
3. Intracardiac right to left shunt;

Primary outcomes:
measure: ultrasound
timeFrame: 2023.05
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT04500509: Diclofenac Potassium With or Without Vaginal Dinoprostone Prior to Hysterosalpingography
Official title: Diclofenac Potassium With or Without Vaginal Dinoprostone Prior to Hysterosalpingography in Primarily Infertile Patients: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility, Female
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2020-08-05
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: double blind placebo controlled trial
Primary purpose: PREVENTION

Brief summary: The aim of our study is to determine the efficacy of oral diclofenac potassium with or without vaginal dinoprostone prior to hysterosalpingography in primarily infertile patients on the pain scores during HSG.

Detailed description: hysterosalpingography is a diagnosis procedure in the evaluation of infertile women and considered to be the traditional and the gold standard in the assessment of the patency of the fallopian tubes. The major disadvantage of hysterosalpingography is pain. In a study reported the patients complained of moderate to severe pain during the procedure. It is reported that some patients undergoing hysterosalpingography was more stressful and anxiety and effect on pain scores.

Eligibility criteria: Inclusion Criteria:

* primary infertility female came for HSG

Exclusion Criteria:

* any patient has contraindication to HSG

Primary outcomes:
measure: Mean pain score during hysterosalpigography by visual analog scale
timeFrame: 15 minutes
Secondary outcomes:
measure: Intensity of pain
timeFrame: 30 minutes after the procedure
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
Study officials:
affiliation: Aswan universirty
name: nahla w Shady, md
role: STUDY_CHAIR
References:
Clinical trial NCT01865409: Effect of Kangaroo Care on Heart Rate Variability
Official title: Does Kangaroo Care Effects on Heart Rate Variability in Neonates
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Immaturity
Oral Intolerance
Postnatal Adaptation
Keywords: Newborn
Prematures
Feeding difficulty
Kangaroo Care
Heart rate variability
Lead sponsor: Fatih University
Sponsor class: OTHER
First posted: 2013-05-30
Enrollment: 30
Sex: ALL
Minimum age (years): 32
Maximum age (years): 35
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Physiological processes leading to a preterm infant to be able to feed orally has not been fully understood. The investigators hypothesized that maturation of autonomic nervous system may play a major role in this process and kangaroo care may accelerate this maturation. The investigators will use heart rate variability to measure the maturation of autonomic nervous system.


Eligibility criteria: Inclusion Criteria:

* Premature infants between 32 t0 35 weeks old
* After 7 days of extra-uterine life

Exclusion Criteria:

* Sepsis, infection
* Cardiac disease
* Intraventricular hemorrhage, patent ductus arteriosus, necrotizing enterocolitis

Primary outcomes:
measure: HRV-Sympathetic-Short Measurement-LF
timeFrame: 5 Minutes
Secondary outcomes:
measure: Time Domain Measurements of HRV
timeFrame: 5 Minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Fatih University School of Medicine
Study officials:
affiliation: Neonatologist
name: Mehmet Kenan Kanburoglu, MD
role: STUDY_DIRECTOR
affiliation: Neonatologist
name: Mehmet Nevzat Cizmeci, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Neonatologist
name: Mustafa Mansur Tatli, MD, Prof
role: STUDY_CHAIR
References:
citation: Srinivasan L, Harris MC. New technologies for the rapid diagnosis of neonatal sepsis. Curr Opin Pediatr. 2012 Apr;24(2):165-71. doi: 10.1097/MOP.0b013e3283504df3.
citation: Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.
citation: Harrison TM. Trajectories of parasympathetic nervous system function before, during, and after feeding in infants with transposition of the great arteries. Nurs Res. 2011 May-Jun;60(3 Suppl):S15-27. doi: 10.1097/NNR.0b013e31821600b1.
Clinical trial NCT05157009: Immediate Implant Outcomes With and Without Bone Augmentation
Official title: Immediate Implants in Damaged Sockets With Simultaneous Bone Reconstruction vs. Immediate Implants in Intact Sockets and no Reconstruction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tooth Loss
Bone Loss, Alveolar
Dental Diseases
Dental Trauma
Keywords: immediate dental implant
dental implant
bone regeneration
peri-implantitis
Lead sponsor: Verdugo, Fernando, DDS
Sponsor class: INDIV
First posted: 2021-12-14
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate immediate implant placement feasibility and esthetic outcomes in severely damaged sockets that received simultaneously bone reconstruction (cortical bone shield) and implant placement versus intact sockets that needed no reconstruction and had immediate implant placement.

Detailed description: The present clinical trial aims at demonstrating facial bone regeneration on sites that presented large buccal bone dehiscences \& vertical bone loss and evaluate the feasibility of performing simultaneous bone augmentation and implant placement, comparing the outcomes with sites that had intact sockets that did not require reconstruction. A secondary objective was to evaluate pink esthetics and marginal bone levels at final follow-up.

Eligibility criteria: Inclusion Criteria:

* individuals 20 Years and older
* Patients requiring single implants to replace missing teeth to restore masticatory function and esthetics.
* ASA1 or ASA2 (American Society of Anesthesiologists)
* Healthy individuals with good oral hygiene and motivation
* No systemic uncontrolled diseases
* Not taking drugs known to modify bone metabolism

Exclusion Criteria:

* Individuals with untreated \& generalized severe periodontitis
* Smokers (\>5 cigarettes/day)
* Poor oral hygiene
* Diabetes (HbA1C \>6.5% as cutoff value)
* Uncontrolled cardiovascular disease
* Poor overall health (ASA IV)

Primary outcomes:
measure: Evaluate implant placement feasibility & success rate at 12 months
timeFrame: 12 months
measure: Number of individuals with low pink esthetic outcomes as assessed by pink esthetic scores (PES)
timeFrame: 12 months
Secondary outcomes:
measure: Implant transparency: clinical presence or absence
timeFrame: 12 months
measure: Number of participants with >0.2mm of marginal bone levels
timeFrame: 12 months
measure: Band of keratinized tissue: clinical presence or absence
timeFrame: 12 months
Other outcomes:
Locations:
city: San Gabriel
country: United States
facility: FV, DDS,Corp
state: California
Study officials:
affiliation: Verdugo, Fernando, DDS
name: Verdugo, PhD
role: PRINCIPAL_INVESTIGATOR
References: